baber/WOPTO huggingface dataset:
Patent NZ-556682-A (NZ)
Title: Safety syringe
Inventor: MOORE COLIN CAMPBELL MARSHALL
IPC: A61M5/19
Filed: 2005-12-22
Abstract: A syringe system includes a first compartment 211 holding a first substance 212 and a second compartment 213 holding a second substance 214. From the position illustrated at stage 1 the second compartment is pushed toward the first compartment a small distance so that the piercing needle 221 pierces the sliding seal 218 of the first compartment. The plunger 223 is then pushed down to break open a seal 227 at the top of the piercing needle and push the substance 214 in the second compartment into the first compartment through the piercing needle to form a mixed substance 225 in the first compartment (stage 3). Finally the second compartment is pushed into the first compartment (stage 4) acting as a plunger so that the mixed substance is forced out of the first compartment to be ejected from the syringe into an injection needle 216.
Patent NZ-562687-A (NZ)
Title: A method of providing a drink container lid for delivering promotional material, a drink container lid containing promotional material in a predetermined orientation, and a labelling apparatus for applying a printed label to a drink container in a predetermined orientation
Inventor: TJHAI PHIN
IPC: G09F3/10
Filed: 2005-10-26
Abstract: A method of providing a device for delivering promotional or advertising information, a device for delivering a message, and a labelling apparatus for labelling drinks container lids with printed labels is disclosed. The method comprises the steps of: (a) providing a drink container lid, and (b) affixing a printed label to the top surface of the drink container lid in a predetermined orientation. The drink container lid covers a mouth of a cup-type container, where the drink container lid comprises a top surface and a passageway, spout or opening that enables fluid to pass therethrough. The printed label is affixed to the top surface of the drinks container lid, where the printed label bears promotional or advertising information. The printed label is affixed by an automated labelling machine adapted to affix the label in a predetermined orientation with respect to the passageway, spout or opening of the lid such that when orienting the passageway, spout or opening towards the consumer, the printed label is located further away from the consumer than the passageway, spout or opening and the orientation of the printed label enables the consumer to comprehend any printed matter on the label without needing to rotate the lid.
Patent NZ-566087-A (NZ)
Title: Novel crystalline form of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4, 5-b]indole-1-acetamide
Inventor: ROCCO WILLIAM L
IPC: A61K31/5025
Filed: 2006-08-24
Abstract: Disclosed is a crystalline form of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide of formula (A) which is designated Form II, that exhibits an X-ray diffraction pattern comprising a peak at about 5.71 degrees 2-theta. Also disclosed is the use of said crystalline form in the treatment or prevention of neurodegenerative diseases, neuropathy, cancer or tumors, cutaneous stress, rheumatoid arthritis, cardiac disease or a cardiac disorder.
Patent NZ-568479-A (NZ)
Title: Homo- and heterocyclic compounds suitable as CETP inhibitors
Inventor: SALVATI MARK E
IPC: C07C211/29
Filed: 2006-11-16
Abstract: Disclosed is a compound of formula Ia or Ib, or a stereoisomer or salt thereof, wherein A is a substituted phenyl group and B is a group containing an aromatic ring and each is chosen from a given list, and R1 is as defined in the specification. Also disclosed is the use of the compound for inhibiting the cholesteryl ester transfer protein or inhibiting remnant lipoprotein production, and for treating disorders such as Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia.
Patent NZ-573687-A (NZ)
Title: C-phenyl glycitol compound for the treatment of diabetes
Inventor: KAKINUMA HIROYUKI
IPC: A61K31/351
Filed: 2007-05-18
Abstract: Disclosed is a C-phenyl glycitol compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, or a hydrate thereof wherein R1 and R2 are the same or different and represent a hydrogen atom, a hydroxyl group, an alkyl group, an alkoxy group or a halogen atom, R3 is a hydrogen atom, a alkyl group, a alkoxy group or a halogen atom, Y is a alkylene group, -O-(CH2)n- (n is an integer of 1 to 4) or a alkenylene group and the further substituents are as defined in the specification. Also disclosed is a composition comprising said compound and the use of said compound in the manufacture of a medicament for the treatment of diabetes.
Patent NZ-582761-A (NZ)
Title: Smoking article with a metallic heat honducting element which contacts, surrounds and links a combustible heat source and an aerosol generating substrate
Inventor: MAEDER SERGE
IPC: A24D1/22
Filed: 2008-08-08
Abstract: 582761 Disclosed is a smoking article which has a combustible heat source, an aerosol-generating substrate downstream of the combustible heat source, and a heat-conducting element around and in contact with a rear portion of the combustible heat source and an adjacent front portion of the aerosol-generating substrate. The aerosol-generating substrate extends at least about 3 mm downstream beyond the heat-conducting element.
Patent NZ-583527-A (NZ)
Title: Adaptor fitting for use with metal tubing in a jacket of a tubing containment system
Inventor: ROLLAND STIRLING KEITH
IPC: F16L25/00
Filed: 2008-09-10
Abstract: Disclosed is a fitting for use with metal tubing in a jacket, which relates generally to piping systems and in particular to a fitting for use with a tubing containment system, wherein the fitting comprises: an adaptor having exterior threads at a first adaptor end, the adaptor having a longitudinal passage for fluid flow; a body having interior threads at a first body end, the interior threads engaging the exterior threads to secure the adaptor to the body in a first body cavity; a jacket lock ring being a separate element from the body, the jacket lock ring positioned at a second body end, the jacket lock ring including barbs, the barbs for engaging a surface of jacket; and a vent opening formed through an exterior wall of second body cavity for receiving the tubing,wherein the body includes a frusto-conical recess at a distal portion of the second body end, the jacket locking ring positioned in the frusto-conical recess.
Patent NZ-585588-A (NZ)
Title: Mycoplasma bovis vaccine
Inventor: BECK MICHAEL
IPC: A61K39/02
Filed: 2008-10-29
Abstract: Disclosed is an attenuated, avirulent Mycoplasma bovis bacterium strain, wherein the attenuated, avirulent Mycoplasma bovis strain is selected from the group consisting of the attenuated Mycoplasma bovis bacteria strains deposited with the ATCC under accession numbers PTA-8694, PTA 8695, or PTA 8696, and any attenuated, avirulent Mycoplasma bovis bacterium strain capable of inducing a humoral immune response in a calf within 14 days after administration of one dose of 2.1E9 CFU via the subcutaneous or intranasal route to the calf, and which does not cause clinical signs normally caused by an infection with a pathogenic Mycoplasma bovis wild-type strain. Further disclosed is a method of attenuating Mycoplasma bovis, comprising, a. passaging Mycoplasma bovis bacteria more than 10 times; b. obtaining the cultured Mycoplasma bovis bacteria; c. testing the cultured Mycoplasma bovis bacteria obtained under step b) for their pathogenicity and immunogenicity, wherein the immunogenic testing comprises: A. infecting cattle with the passaged Mycoplasma bovis bacteria B. monitoring the development of the humoral antibody response against Mycoplasma bovis in the infected cattle; d. propagating the non-pathogenic, but immunogenic Mycoplasma bovis bacteria to obtain the attenuated Mycoplasma bovis bacteria. Further disclosed is an immunogenic composition comprising live bacteria of an attenuated, avirulent Mycoplasma bovis bacterium strain, wherein the bacteria have been passaged more than 10 times, adapted for the treatment or prophylaxis of infections caused by Mycoplasma bovis in cattle or for reducing the severity or incidence of clinical signs caused by Mycoplasma bovis in cattle.
Patent NZ-585663-A (NZ)
Title: Running a browser application at a server and streaming interactive video to a user of the browser with low latency over a network
Inventor: PERLMAN STEPHEN G
IPC: G06F15/16
Filed: 2008-12-04
Abstract: Disclosed is a method for accelerated web page delivery. The method includes running a web browsing application on one or more servers, the web browsing application being used by a user located a remote distance from the one or more servers. The user interacts with the browsing application via compressed streaming interactive video transmitted over one or more networks. The method also includes providing the user with access to at least one web page of a website via the web browser application, the at least one web page comprising one or more files which include content. The at least one web page is displayed on a client device associated with the user in response to a user request. The method includes displaying the content of the at least one web page in response to the user request with a worse-case latency of 90 milliseconds when the remote distance between the user and the one or more servers is 1500 miles or less.
Patent NZ-590405-A (NZ)
Title: Apparatus and method of making a heel-less nail with nail shaft offset eccentrically from head for one side flush
Inventor: GABRIEL WILLIAM L
IPC: B21G3/12
Filed: 2009-05-26
Abstract: 590405 A full-round head nail having an offset head is configured with a gusset formed integrally between an undersurface of the offset head and a superior portion of a shank. The head of the nail is relatively thin, and the shank is positioned radially off center of the round head such that no heel is formed at a point tangential to both the head and the shank. The gusset has a lofted surface tapering radially from a roundness at the zero heel to a taper at the toe. The gusset reinforces the junction of the shank with the head, supports the toe of the head, and distributes the force of a load on the head through a longitudinal axis of the shank, preventing the toe from bending or yielding and prevents the shank from yielding to the stresses of the load applied.
Patent NZ-590952-A (NZ)
Title: Use of opioid antagonists for treating urinary retention
Inventor: HOPP MICHAEL
IPC: A61K31/00
Filed: 2009-07-07
Abstract: Disclosed is the use of at least one opioid antagonist or a pharmaceutically acceptable salt thereof and at least one opioid agonist or a pharmaceutically acceptable salt thereof in the manufacture of a dosage form for treating urinary retention (ischuria). Specific examples of an opioid antagonist include naloxone, naltrexone and nalbuphine. Specific examples of an opioid agonist include oxycodone, morphine, hydromorphone and oxymorphone.
Patent NZ-592103-A (NZ)
Title: Smoking article with a sheet material which has a diluent to dilute emissions from the tobacco rod
Inventor: WOODCOCK DOMINIC
IPC: A24D1/02
Filed: 2009-09-21
Abstract: 592103 Disclosed is a smoking article (10) with a rod of smokeable material (11) and a sheet material (13) comprising at least one diluent and at least one adsorbent. The diluent is present in an amount effective to dilute emissions from the rod of smokeable material during combustion.
Patent NZ-592368-A (NZ)
Title: Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
Inventor: CLEARY P
IPC: C07K14/315
Filed: 2009-11-04
Abstract: NZ 592368 Disclosed is an immunogenic composition comprising a mixture of: an SCP polypeptide encoded by a nucleic acid sequence as defined in the complete specification; at least one other polypeptide encoded by a nucleic acid sequence having at least 90% identity to a nucleic acid sequence of nucleic acid of ORF 554 as defined in the complete specification; and a physiologically-acceptable vehicle. Also disclosed is the use of said composition in the manufacture of an immunogenic composition for protecting a susceptible mammal against colonisation or infection by beta-hemolytic streptococci.
Patent NZ-592963-A (NZ)
Title: Composition for controlling pests comprising ethaboxam and neonicotinoid compounds
Inventor: KURAHASHI MAKOTO
IPC: A01N43/78
Filed: 2009-11-20
Abstract: Disclosed are compositions for controlling plant disease comprising ethaboxam and a neonicotinoid compound of formula (1), wherein the substituents are as defined within the specification. Examples of neonicotinoid compounds of formula (1) include clothianidin, imidacloprid and thiamethoxam. Further disclosed is a method for controlling plant diseases which comprises said composition, and a plant seed treated with effective amounts of said composition.
Patent NZ-594479-A (NZ)
Title: Diagnosis and treatment of gastric-type cancers with siRNA, modified antibodies, or immunotherapy approaches
Inventor: SAHIN UGUR
IPC: A61K31/713
Filed: 2010-02-18
Abstract: Patent No. 594479 Disclosed is the use of an inhibitor of expression and/or activity of a tumor antigen for the preparation of a pharmaceutical composition for treating or preventing a tumor disease, wherein said tumor antigen comprises an amino acid sequence encoded by a nucleic acid which comprises the nucleic acid sequence according to SEQ ID NO: 1 of the sequence listing or a variant of said nucleic acid sequence, wherein (i) the inhibitor of expression of a tumor antigen is an inhibitory nucleic acid selectively hybridizing to the nucleic acid which comprises the nucleic acid sequence according to SEQ ID NO: I of the sequence listing or a variant of said nucleic acid sequence, or (ii) the inhibitor of activity of a tumor antigen is an antibody specifically binding to said tumor antigen, wherein said variant is a functional variant and said tumor disease is a cancer of the stomach, a gastric cancer, a gastric carcinoma, an adenocarcinoma of the stomach or a metastasis thereof.
Patent NZ-597108-A (NZ)
Title: Prodrugs of nh-acidic compounds
Inventor: BLUMBERG LAURA COOK
IPC: A01N43/00
Filed: 2010-06-24
Abstract: 597108 Disclosed herein is a method of sustained delivery of a lactam, imide, amide sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties as defined by formulae I, II and II wherein the variables are defined in the specification. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
Patent NZ-597940-A (NZ)
Title: Method for making 3alpha-hydroxy, 3beta- methyl-5alpha-pregnan-20-one (ganaxolone)
Inventor: SHAW KENNETH
IPC: A61K31/57
Filed: 2010-08-11
Abstract: 597940 Disclosed herein is a method the manufacture of 3alpha-hydroxy, 3beta-methyl-5alpha-pregnan-20-one (ganaxolone) comprising: reacting 5alpha-pregnane-3,20-dione (Dione 2) with an organometallic methylating agent in an inert solvent and thereby obtaining ganaxolone, wherein the organometallic methylating agent contains iron, titanium or a combination thereof. The method additionally comprising heating the obtained ganaxolone in an organic solvent, such as ethyl acetate, to obtain purified ganaxolone. The method additionally comprising generating the organometallic methylating agent by adding about 2 to about 4 equivalents of methyl magnesium halide or methyl lithium to a solution of anhydrous ferric halide or anhydrous ferrous halide in the inert solvent and thereby forming the organometallic methylating agent(s). The method additionally comprising adding lithium chloride to iron halide in the inert solvent prior to generating the organometallic methylating agent, wherein the amount of lithium chloride added is about 0.1 to about 4 equivalents of lithium chloride to equivalent of iron halide. The method wherein the organometallic methylating agent is dimethyl iron (Me2Fe), methyl triethoxy titanium, methylchloro diethoxy titanium ((CH3)Cl(CH3CH2O)2Ti), methyl trichlorotitanium (CH3Cl3Ti), tetramethyltitanium ((CH3)4Ti), dimethyl dichloro titanium ((CH3)2Cl2Ti), trimethyl chlorotitanium ((CH3)3ClTi) or methyl iron chloride (CH3FeCl). The method wherein the organometallic methylating agent is an ate complex containing a (Me)3Fe- anion and either lithium or MgX as a cation, wherein X is a halide.
Patent NZ-622977-A (NZ)
Title: Kettle
Inventor: KHOURY EDWARD JOSEPH
IPC: A47J27/21
Filed: 2012-08-29
Abstract: A kettle (10) comprising a base (12) and a frame (18) pivotally mounted relative to the base. The frame includes first electrical contacts connectable to a power source and a vessel (16) is receivable in and removable from the frame. The vessel includes an internal element in connection with second electrical contacts and an opening (40) from which liquid can be poured. When the vessel is received in the frame the first electrical contacts make connection with the second electrical contacts such that power is supplied to the internal element to heat water within the vessel. Pivoting of the vessel and frame relative to the base allows pouring of liquid from the opening.
Patent NZ-702967-A (NZ)
Title: Diclofenac formulations
Inventor: GRENIER ARNAUD
IPC: A61P29/00
Filed: 2013-07-04
Abstract: The subject invention provides improved diclofenac gel formulations comprising, inter alia, at least 3% wt of diclofenac and at least 3% wt of a fatty alcohol, which provides improved diclofenac delivery across the skin and enables a reduced frequency of administration of the diclofenac gel formulations. The improved diclofenac gel formulations of the present invention may be used in the treatment of both localised and systemic conditions, including treatment of pain and inflammatory disorders.
Patent NZ-705983-A (NZ)
Title: Fc containing polypeptides with altered glycosylation and reduced effector function
Inventor: QIU HUAWEI
IPC: C07K16/28
Filed: 2013-09-12
Abstract: Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
Patent NZ-706992-A (NZ)
Title: Chocolate product
Inventor: GAIM-MARSONER GUNTHER
IPC: A23G1/50
Filed: 2013-12-06
Abstract: There is described a method of manufacturing an edible product comprising chocolate, the method comprising the steps of: (a) providing a baking mixture, for example a liquid batter or a pasty mass, comprising a source of starch and a liquid chocolate; (b) baking the baking mixture in a baking apparatus; wherein the liquid chocolate provides up to 70 wt% of the baking mixture. Edible products, including wafers and extruded snack foods, produced by such a method are also described.
Patent NZ-708860-A (NZ)
Title: Use of antisecretory factor (af) in glioblastoma treatment
Inventor: HANSSON HANS-ARNE
IPC: A61P35/00
Filed: 2013-12-20
Abstract: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for treating glioblastoma. In one embodiment, AF proteins are used for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an immunoactive compound or a drug targeting posttraumatic injury, neurodegeneration, or an inflammatory condition.
Patent NZ-712963-A (NZ)
Title: Vertical take-off and landing aircraft
Inventor: TSUNEKAWA MASAYOSHI
IPC: B64C29/00
Filed: 2014-05-15
Abstract: A vertical take-off and landing aircraft includes a propulsion mechanism 2 that generates lift and thrust, a main frame 4 that supports seating 41 and a landing undercarriage 42, a sub-frame 5 which supports the propulsion mechanism 2 and is arranged so as to be swingable back and forth relative to the main frame 4, a motive power supply unit 3 supported by the main frame 4 and supplying motive power to the propulsion mechanism 2, a control stick 6 connected to the sub-frame 5, and a main wing 7 arranged on the propulsion mechanism 2, wherein the main wing 7 is formed to be retracted to a position not interfering with an air flow of the propulsion mechanism 2 in a normal time and to be movable to a position where lift is generated when thrust is lost. Gliding is made possible even if thrust is lost while increasing in size of a fuselage is avoided.
Patent NZ-714433-A (NZ)
Title: High temperature geomembrane liners and master batch compositions
Inventor: PRACHOOMDANG YONGYOOT
IPC: C08J3/22
Filed: 2014-05-20
Abstract: Geomembrane liners suitable for use at elevated temperatures up to 100 °C to enhance the service life of the geomembrane liners, as well as master batch compositions suitable for preparing such geomembrane liners, and compositions for preparing a geomembrane liner for a containment system, wherein said composition is of: 1) a master batch; and 2) a base resin and wherein said composition comprises: i) about 8-10 wt% of a master batch composition comprising a) about 70 to about 80 wt% of a Linear Low Density Polyethylene (LLDPE), Medium Density Polyethylene (MDPE), High Density Polyethylene (HDPE), or Polyethylene of Raised Temperature (PERT) resin carrier has density from 0.910 to 0.955 g/cm3. b) about 1 to about 3 wt% of a primary antioxidant, wherein said primary antioxidant comprises 1,3,5-trimethyl-2,4,6-tris-(3,5-di-t-butyl-4- hydroxybenzyl) benzene; c) about 0.1 to about 0.5 wt% of a secondary antioxidant, wherein said secondary antioxidant comprises pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4- hydroxyphenyl)propionate); d) optionally, about 0.1 to about 0.5 wt% of tris (2,4-di-tert-butylphenyl) phosphite; e) about 1 to about 3 wt% of a UV stabilizer, wherein said UV stabilizer comprises a hindered amine light stabilizer; f) about 0.1 to about 0.5 wt% of an acid neutralizer; and g) about 20 to about 30 wt% of a carbon black, wherein said carbon black is a furnace carbon black, and wherein the percentages by weight add up to 100% and are based on the total weight of the master batch composition; and ii) about 90 to about 92 wt% of a base resin composition comprising Polyethylene of Raised Temperature (PERT) base resin, wherein the percentage by weight is based on the total weight of the geomembrane composition.